Haemonetics Corporation (HAE), a healthcare company, on Thursday revised its fiscal 2026 outlook.
For the full year, the company now expects adjusted income of $4.90 to $5 per share, compared with the prior guidance of $4.80 to $5 per share.
Haemonetics now anticipates its annual revenue to decline 1% to 3%, compared with the earlier expectation for a decline of 1% to 4%.
For fiscal 2025, the company had posted adjusted income of $4.57 per share, with revenue of $1.361 billion.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.